Please login to the form below

Not currently logged in
Email:
Password:

Merck earmarks €35m for Italian biologics site development

Pharma firm plans new biotech production line at its Bari facility

Bari

Merck KgAa is set to invest €35m to expand its manufacturing site in the town of Modugno, Bari in Italy, to add a new production line for aseptic filing of biologics.

Expected to be fully operational by 2022, the new production line will support the growth of the company’s biotech medicines portfolio.

Stefan Oschmann, chairman of the executive board and CEO of Merck, said: “This investment underpins the importance of the Modugno-Bari production site for our growing healthcare business.”

Modugno is one of 15 manufacturing sites in operation by Merck and the facility currently employs around 225 people.

Oschmann added: “It will help us to secure the supply of medicines that improve people’s lives around the world.”

The new production line - which is expected to pump out 14 million units per year - will be used for biologic medicines for several disease areas including multiple sclerosis, fertility and endocrinology.

The move builds on a 2014 investment made by the pharma firm that saw it inject €50m into the site for a fully automated production line using isolator technology, as well as an automated warehouse.

Article by
Gemma Jones

10th October 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....